Aprea Therapeutics
Presença
Aprea Therapeutics é uma empresa listada sob o símbolo APRE (SE).
Executivos
Veja o organograma con seus 10 executivos principais
Biografias mais buscadas da Aprea Therapeutics
- Oren Gilad, President and Chief Executive Officer
- Christian Schade, Chairman of the Board
- Marc Duey, Director
Criar um alerta
para seguir os movimentos de executivos da Aprea Therapeutics.
Farmacêutica
Aprea Therapeutics possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Aprea Therapeutics
- Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com | Aprea Therapeutics
- Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548 | Aprea Therapeutics
- Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors | Aprea Therapeutics
- Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes | Aprea Therapeutics
- Aprea Therapeutics to Present at Upcoming Investor Conferences | Aprea Therapeutics
- Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations | Aprea Therapeutics
- Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML) | Aprea Therapeutics
- Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors | Aprea Therapeutics
- Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeti
- Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS) | Aprea Therapeutics
- View more press releases Close
Redes sociais sobre Aprea Therapeutics
- Aprea Therapeutics na Wikipedia, Google News e Yahoo Finance
- Aprea Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Oren Gilad 
Ligue para a Aprea Therapeutics em +46 85...
